TherOx, a Irvine, Calif.-based medical device company, seeks $25 million for the final push to bring its treatment to increase the quality of life for heart attack patients. The company’s optimized “super-saturated oxygen” (SSO2) offers a solution to reduce infarct size by increasing oxygen to heart tissue damaged during percutaneous coronary intervention and stenting. Following an FDA advisory panel’s advice to gather more data, TherOx announced very promising results from a pilot study, AMIHOT II, at TCT 2013. They showed a 9.6 percent infarct size at 30 days in high-risk patients treated with its next-generation system for Supersaturated Oxygen (SSO2) Therapy, which surpassed the company’s goal of 15 percent. The goal is to save heart muscle tissue in heart attack patients, thus improving quality of life after a heart attack.
Help employers find you! Check out all the jobs and post your resume.
